(Q33392291)

English

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic idiopathic myelofibrosis

1 reference

based on heuristic

inferred from title

9

object named as

A Tefferi

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

D Caramazza

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K H Begna

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N Gangat

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

R Vaidya

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Siragusa

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D L Van Dyke

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Hanson

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Pardanani

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

82-88

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1038/leu.2010.234

0 references

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Outcome of transplantation for myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Choosing between stem cell therapy and drugs in myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

Validation of cytogenetic-based risk stratification in primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

Risk factors for leukemic transformation in patients with primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2010.234

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33392291&oldid=1606654971"